دورية أكاديمية
أعرض في EDS

Virological Suppression and Its Associated Factors of Dolutegravir Based Regimen in a Resource-Limited Setting: An Observational Retrospective Study in Ethiopia.

التفاصيل البيبلوغرافية
العنوان: Virological Suppression and Its Associated Factors of Dolutegravir Based Regimen in a Resource-Limited Setting: An Observational Retrospective Study in Ethiopia.
المؤلفون: Mehari EA; Department of Clinical Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia., Muche EA; Department of Clinical Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia., Gonete KA; Department of Human Nutrition, Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
المصدر: HIV/AIDS (Auckland, N.Z.) [HIV AIDS (Auckl)] 2021 Jun 29; Vol. 13, pp. 709-717. Date of Electronic Publication: 2021 Jun 29 (Print Publication: 2021).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Dove Medical Press Country of Publication: New Zealand NLM ID: 101515943 Publication Model: eCollection Cited Medium: Print ISSN: 1179-1373 (Print) Linking ISSN: 11791373 NLM ISO Abbreviation: HIV AIDS (Auckl) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Auckland, N.Z.] : Dove Medical Press, c2009-
مستخلص: Background: Toxicity, treatment failure, and resistance to existing HIV treatment regimens have become a challenge in resource-limited settings. As a result, a dolutegravir based regimen has recently been utilized. However, there is a paucity of evidence in sub-Saharan countries regarding its virological suppression. Thus, this study aimed to assess virological suppression and associated factors of dolutegravir based regimen.
Methods: A retrospective follow-up study was conducted on 349 individuals. They were selected using a systematic random sampling technique among all treatment-experienced adult HIV patients who were on a dolutegravir based regimen. From this, 81.4% of them were virologically suppressed before the initiation of dolutegravir based regimen. The study was carried out at twelve months of therapy after shifting to dolutegravir based regimen (TDF-3TC-DTG) during the period May 2018-August 2020 at Debre Markos referral hospital. Retrospective data before and after dolutegravir based regimen initiation were collected from their medical records. The time on dolutegravir based regimen was one year. Bivariable and multivariable logistic regression was used to identify factors. Variables with p <0.05 were considered statistically significant.
Results: From a total of 359, 349 participated (97.2%) in the study, and the mean age of the participants was 40.28 ±11.6 years. Totally, 192 (55.0%) of them were female. The proportion of virological suppression was 92%. Good adherence (participants who reported an intake of ≥95% of the prescribed medication) (AOR=6.2, 95% CI: 1.93, 20.11) and overall duration of ART (AOR=1.02, 95% CI: 1.01, 1.04) were associated with virological suppression.
Conclusion: Dolutegravir based regimen maintains high virological suppression. Adherence and duration of ART were associated with virological suppression. Therefore, designing effective mechanisms to maintain virological suppression is important.
Competing Interests: The authors declare that they have no conflicts of interest for this work.
(© 2021 Mehari et al.)
References: AIDS Res Hum Retroviruses. 2016 Oct/Nov;32(10-11):955-963. (PMID: 26892622)
Int J Infect Dis. 2020 Aug;97:151-158. (PMID: 32497804)
Am J Clin Nutr. 2010 Jun;91(6):1642-8. (PMID: 20357043)
PLoS One. 2019 Feb 5;14(2):e0211344. (PMID: 30721233)
PLoS One. 2019 Sep 10;14(9):e0222229. (PMID: 31504060)
HIV AIDS (Auckl). 2017 Aug 08;9:153-159. (PMID: 28848364)
BMC Public Health. 2014 Oct 04;14:1035. (PMID: 25280535)
PLoS One. 2020 May 27;15(5):e0232419. (PMID: 32459822)
N Engl J Med. 2011 Aug 11;365(6):493-505. (PMID: 21767103)
Lancet. 2013 Aug 24;382(9893):700-8. (PMID: 23830355)
Lancet HIV. 2019 Jun;6(6):e355-e363. (PMID: 31068270)
JAMA. 2004 Sep 8;292(10):1232-4. (PMID: 15353537)
N Engl J Med. 2013 Nov 7;369(19):1807-18. (PMID: 24195548)
HIV AIDS (Auckl). 2012;4:117-24. (PMID: 22893751)
AIDS. 2019 Aug 1;33(10):1673-1674. (PMID: 31305333)
J Clin Virol. 2015 Mar;64:12-5. (PMID: 25728072)
N Engl J Med. 2019 Aug 29;381(9):816-826. (PMID: 31339676)
Clin Infect Dis. 2006 Mar 15;42(6):862-9. (PMID: 16477566)
AIDS. 2014 Mar 27;28(6):813-9. (PMID: 24463394)
Clin Infect Dis. 2020 Mar 17;70(7):1267-1274. (PMID: 31100116)
BMC Infect Dis. 2019 May 30;19(1):484. (PMID: 31146698)
Antivir Ther. 2017;22(4):295-305. (PMID: 28401876)
BMC Infect Dis. 2020 Jan 2;20(1):4. (PMID: 31898535)
J Acquir Immune Defic Syndr. 2017 Dec 15;76(5):527-531. (PMID: 28825943)
J Antimicrob Chemother. 2019 Oct 1;74(10):3021-3029. (PMID: 31257432)
Antivir Ther. 1999;4(3):157-61. (PMID: 12731755)
AIDS. 2020 Jan 1;34(1):109-114. (PMID: 31567162)
Drugs. 2014 Jul;74(11):1241-52. (PMID: 25005775)
فهرسة مساهمة: Keywords: Debre-Markos; HIV; dolutegravir; virological suppression
تواريخ الأحداث: Date Created: 20210708 Latest Revision: 20220424
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC8254547
DOI: 10.2147/HIV.S316776
PMID: 34234572
قاعدة البيانات: MEDLINE
الوصف
تدمد:1179-1373
DOI:10.2147/HIV.S316776